The UAB Institutional Biosafety Committee Meeting Minutes
Research Involving Recombinant and Synthetic Nucleic Acid Molecules
January 08, 2026 9:00 am

Members	Present (Y/N)	Vote (Y/N)
1. Joel N. Glasgow, PhD, Chair [JNG]	Y	Y
2. Megan Kiedrowski, PhD, Vice-Chair [MRK]	Y	Y
3. Donna Williamson, MS, RSS [DSW]	Y	Y
4. Amanda F. Smith, BS, RSS, Voting Contact [AFS]	Y	N
5. Cameron Crosby, MD, OM [JCC]	N	N
6. Julie Allen, DNP, OM [JSA]	Y	Y
7. Lillie Flood, RN-BSN, JCDH [LF]	Y	Y
8. Qiang (John) Ding, PhD, VA [QJD]	Y	Y
9. Andrea Osborne, DVM, ARP [AJO]	Y	Y
10. Justin Roth, PhD, EHS [JCR]	Y	N
11. Brian Lagory, BS, BSO-EHS [BEL]	Y	Y
12. Vineel Reddy, PhD, EHS [VPR]	Y	Y
13. Julie Gray, BS, EHS [JDG]	Y	N
14. Tyler Uzzell, MA, IRB [TWU]	Y	Y
15. Amanda J. Watts, MS, IACUC [AJW]	Y	Y
16. Chad Dunaway, IACUC [CD]	N	N
17. Tyler T. Wright, PhD, Lab Rep [TTW]	Y	Y
18. Masakazu Kamata, PhD, Lab Rep [MK]	Y	Y
19. Kevin Harrod, PhD, Lab Rep [KH]	N	N
20. Christine M. Wright, PhD, Lab Rep [CMW]	N	N
21. Larisa Pereboeva, PhD, Lab Rep [LP]	N	N
22. Theresa Strong, PhD, Lab Rep [TVS]	Y	Y
23. Aftab Ahmad, PhD, Lab Rep [AA]	Y	Y
24. Adam McClintock, MBA, HSR [AM]	N	N
25. Wesley Willeford, MD, JCDH [WW]	Y	Y
26. Rebecca Johnstone, RSS, Recording Secretary [RMJ]	Y	N
Total	**20**	**16**

Guests Present

Laura Caltrider, MS, EHS [LPC]
Earle Durboraw, MA, ARP [EBD]
Joseph Palmer, PhD, SEBLAB [JP]
Ian Doty, EHS [ID]
Caitlyn Sebastian, Biomed Sciences [CS]
Douglas Fox, PhD, SEBLAB [DMF]
Luselyz Ortiz Torres, EHS [LOT]
Dale Payton, ARP [DP]

The January 08, 2026, Institutional Biosafety Committee (IBC) meeting for Research Involving Recombinant of Synthetic Nucleic Acid Molecules was called to order at 9:03 am via web-based video conferencing tool by JNG. A quorum was present.

Welcome and Introduction of Guests

JNG welcomed all in attendance.

Approval of the December 08, 2025, Minutes

The December 08, 2025 meeting minutes were distributed in the Committee member packet via email and/or secure cloud storage prior to the meeting. A motion was made to approve the minutes. The motion was seconded. There was one abstention. The minutes were approved.

Standing Reports

- In the News/Regulatory Visits – There were no updates.
- Faculty Senate – There were no updates.
- Veterans Administration – There were no updates.
- Employee Health – Flu shots available through Occupational Medicine
- JCDH – There were no updates.
- IRAP and EHSA – There were no updates.
- Research Safety Updates:
  - PI Arrivals/Departures/UAB Lab Relocations – Arrivals: N/A Departures: N/A
  - Safety Visits – Top 5 Violations: Chemical inventory, peroxide formers mislabeled, usage logs improperly updated, and improper chemical storage

New/Old Business – ARP updated on autoclave maintenance.

Project Review - The review and discussion of the following projects included: agent characteristics; types of manipulations planned; verification that the PI and laboratory staff performing the research have been appropriately trained in the safe conduct of the research; and containment control measures to be implemented (biosafety level and any special provisions). Please refer to the attached summary of the Committee review outcome for each project.

Transgenic Projects - No transgenic projects were discussed at this meeting.

Adjournment - The Chair asked if there were any further questions or comments. Being none, the meeting was adjourned at 9:50 am. The next meeting date is February 12, 2026, 9:00 am.

Respectfully submitted by:

Rebecca Johnstone, Recording Secretary
Research Safety Committees

Project registration documents submitted by the PI indicate UAB Institutional Biosafety Committee (IBC) review and approval is required for the following research activities involving recombinant or synthetic nucleic acid (r/sNA) molecules and/or biohazardous agents. If the nature of the work changes or the listed conditions cannot be met, it is the PI's responsibility to consult with the IBC for additional guidance. It is the PI's responsibility to ensure all individuals listed on the project are enrolled in and compliant with the requirements of UAB Employee Health prior to and for the duration of the work:

Approve	Disapprove	Abstain or Recuse	RSC #	Evaluation
16	--	--	25-217	**(III.C.1) Susan Bal; *UAB 2595 - A Phase 1b Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants with Newly Diagnosed Multiple Myeloma*** Reason for IBC: • Administration of genetically modified CAR-T cells expressing a single recombinant chimeric T cell receptor molecule that binds BCMA and GPRC5D, to one or more human subjects. The University of Alabama at Birmingham's IBC reviewed the proposed work listed above and has approved the work under the following containment conditions. • Universal Precautions should be followed when handling and administering genetically modified CAR-T cells. • The study drug should be prepared according to the sponsor's Product Administration Manual. • Any potentially infected ancillary materials used for infusion should be disposed as medical waste or per UAB policies and procedures.
16	--	--	25-216	**(III.D.4) YuShin Kim; *Chronic Intermittent Hypoxia and Diabetic Pain*** Reason for IBC: • Administration of recombinant Lactobacillus paracasei to animals. The University of Alabama at Birmingham's IBC reviewed the proposed work listed above and has approved the work under the following containment conditions. • ABSL2 practices and procedures, including the posting of an AUSI, will be used post-administration of recombinant Lactobacillus paracasei. • The Animal Resources Program will be notified, via the posting of an AUSI, of recombinant Lactobacillus paracasei in animals.

16	--	--	25-218	**(III.D.4) YuShin Kim;** ***Lipid Signaling, Temperature Acclimation, and Temperature Hypersensitive Pain Models*** Reasons for IBC: • Administration of recombinant AAV reporter vectors to animals. The University of Alabama at Birmingham's IBC reviewed the proposed work listed above and has approved the work under the following containment conditions. • ABSL2 practices and procedures, including the posting of an AUSI, will be used for 14 days post-administration of AAV vectors, then ABSL1 will be used. • The Animal Resources Program will be notified, via the posting of an AUSI, of AAV vectors in animals.
16	--	--	25-219	**(III.D.4) YuShin Kim;** ***Coupled activation and mutations affecting coupled activation*** Reason for IBC: • Administration of recombinant AAV reporter vectors to animals. The University of Alabama at Birmingham's IBC reviewed the proposed work listed above and has approved the work under the following containment conditions. • ABSL2 practices and procedures, including the posting of an AUSI, will be used for 14 days post-administration of AAV vectors, then ABSL1 will be used. • The Animal Resources Program will be notified, via the posting of an AUSI, of AAV vectors in animals.
16	--	--	25-220	**(III.D.4) YuShin Kim;** ***Cells Targeted by Calcitonin and Insulin-Like Growth Factors in Models of Nerve Injury and Incisional Pain*** Reason for IBC: • Administration of recombinant AAV reporter vectors to animals. The University of Alabama at Birmingham's IBC reviewed the proposed work listed above and has approved the work under the following containment conditions. • ABSL2 practices and procedures, including the posting of an AUSI, will be used for 14 days post-administration of AAV vectors, then ABSL1 will be used. • The Animal Resources Program will be notified, via the posting of an AUSI, of AAV vectors in animals.
16	--	--	25-221	**(III.D.4) YuShin Kim;** ***Cognition and pain sensitivity in aged Fischer 344 rats*** Reason for IBC: • Administration of recombinant AAV reporter vectors to animals.

				The University of Alabama at Birmingham's IBC reviewed the proposed work listed above and has approved the work under the following containment conditions. • ABSL2 practices and procedures, including the posting of an AUSI, will be used for 14 days post-administration of AAV vectors, then ABSL1 will be used. • The Animal Resources Program will be notified, via the posting of an AUSI, of AAV vectors in animals.
16	--	--	25-222	**(III.D.4) YuShin Kim; *Kim Lab Startup*** Reason for IBC: • Administration of recombinant AAV reporter vectors to animals. The University of Alabama at Birmingham's IBC reviewed the proposed work listed above and has approved the work under the following containment conditions. • ABSL2 practices and procedures, including the posting of an AUSI, will be used for 14 days post-administration of AAV vectors, then ABSL1 will be used. • The Animal Resources Program will be notified, via the posting of an AUSI, of AAV vectors in animals.